Provectus Announces Preliminary Phase 2 Data For PH-10 In Its Psoriasis And Atopic Dermatitis Trials
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced preliminary data for the company’s PH-10 Phase 2 clinical trial for Psoriasis as well as for its Phase 2 clinical trial for Atopic Dermatitis. Dr. Craig Dees, Ph.D…
source : www.medicalnewstoday.com
Home Income Profit System
You can make money working from the comfort of your own home!
Get 5 Books for 99 cents!
The most popular books at the most popular prices!
CreditReport.com
Get your credit report and score in just seconds!
Gevalia Stainless Steel Bundle
Save 75% on this Coffee Bundle When You Try Gevalia!
Take the IQ Challenge!
Are you as stupid as your friends think? Prove them wrong with this quick IQ Challenge game!
You can make money working from the comfort of your own home!
Get 5 Books for 99 cents!
The most popular books at the most popular prices!
CreditReport.com
Get your credit report and score in just seconds!
Gevalia Stainless Steel Bundle
Save 75% on this Coffee Bundle When You Try Gevalia!
Take the IQ Challenge!
Are you as stupid as your friends think? Prove them wrong with this quick IQ Challenge game!
Related News:
- ACC: FDA Announces Review of ACCORD Data
- ETEX Corporation Announces FDA Clearance And Launch Of Carrigen(R) Porous Bone Substitute Material
- Graceway Announces Journal Of The American Academy Of Dermatology Publishes Articles On New Short-Course Imiquimod Formulation In Actinic Keratosis
- Auxilium Announces Availability Of XIAFLEXTM For The Treatment Of Dupuytren’s Contracture
- NPS Pharmaceuticals Announces Support For Rare Disease Day Observance
- Health Ranger announces "Healing Miracles LIVE" event in Southern Calif., March 19 – 20, with Horowitz, Whitaker, Gerson and more
- Cytokinetics Announces Non-Clinical Data From Multiple Programs To Be Presented At The Biophysical Society 54th Annual Meeting
- Psyadon Pharmaceuticals, Inc. Announces Regulatory Milestones And The Initiation Of A Clinical Trial Of Ecopipam In Lesch-Nyhan Disease
- Merz Pharma Announces Launch Of Denzapine As First Available Generic For Treatment-Resistant Schizophrenia
- Protalix Announces Presentation Of Phase III Taliglucerase Alfa Data At WORLD Lysosomal Disease Network
Details :
Submited at Monday, December 7th, 2009 at 1:00 am on Dermatology by samantha
Comment RSS 2.0 - leave a comment - trackback
Leave Comment Here...